Literature DB >> 19706697

Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis.

Olalla Robles1, Arantzazu Zabala, Igor Bombín, Mara Parellada, Dolores Moreno, Ana Ruiz-Sancho, Celso Arango.   

Abstract

The primary purpose of this study was to compare changes in cognition in early-onset psychosis after 6-months treatment with quetiapine or olanzapine. This is a randomized, single-blind, 6-month study in 50 adolescents with a diagnosis of early-onset psychosis. Patients were randomized to quetiapine (n = 24) or olanzapine (n =26). A thorough neuropsychological battery was administered at baseline and after 6-month treatment. Out of the total sample included in the study, 32 patients completed at least 6-months treatment with the assigned medication (quetiapine, n =16; olanzapine, n = 16). No changes were observed in cognitive performance after 6-month treatment with quetiapine or olanzapine. Although some trends toward cognitive improvement were observed for the olanzapine group after 6-month treatment, neither group showed statistically significant gains. Furthermore, there was no evidence of any differential efficacy of olanzapine or quetiapine on cognitive improvement in this sample of adolescents with psychosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19706697      PMCID: PMC3044627          DOI: 10.1093/schbul/sbp062

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  53 in total

1.  Effects of quetiapine on cognitive functions in schizophrenia.

Authors:  Berna Binnur Kivircik Akdede; Köksal Alptekin; Arzu Kitiş; Haluk Arkar; Yildiz Akvardar
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-12-24       Impact factor: 5.067

2.  A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

Authors:  Robert W Buchanan; Miriam Davis; Donald Goff; Michael F Green; Richard S E Keefe; Andrew C Leon; Keith H Nuechterlein; Thomas Laughren; Robert Levin; Ellen Stover; Wayne Fenton; Steve R Marder
Journal:  Schizophr Bull       Date:  2005-02-16       Impact factor: 9.306

3.  A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition.

Authors:  Ashok Malla; Ross Norman; Derek Scholten; Laurel Townsend; Rahul Manchanda; Jatinder Takhar; Raj Haricharan
Journal:  Psychiatry Res       Date:  2004-12-15       Impact factor: 3.222

4.  Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.

Authors:  S E Purdon; B D Jones; E Stip; A Labelle; D Addington; S R David; A Breier; G D Tollefson
Journal:  Arch Gen Psychiatry       Date:  2000-03

5.  The course of cognitive functioning in first episode psychosis: changes over time and impact on outcome.

Authors:  Jean Addington; Huma Saeedi; Donald Addington
Journal:  Schizophr Res       Date:  2005-10-01       Impact factor: 4.939

6.  Memory impairment in schizophrenia: a meta-analysis.

Authors:  A Aleman; R Hijman; E H de Haan; R S Kahn
Journal:  Am J Psychiatry       Date:  1999-09       Impact factor: 18.112

7.  Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents.

Authors:  M Davidson; A Reichenberg; J Rabinowitz; M Weiser; Z Kaplan; M Mark
Journal:  Am J Psychiatry       Date:  1999-09       Impact factor: 18.112

Review 8.  On the trail of a cognitive enhancer for the treatment of schizophrenia.

Authors:  Emmanuel Stip; Sylvie Chouinard; Luc Jean Boulay
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2005-01-16       Impact factor: 5.067

Review 9.  Clinical effectiveness of new generation antipsychotics in adolescent patients.

Authors:  Celso Arango; Mara Parellada; Dolores Maria Moreno
Journal:  Eur Neuropsychopharmacol       Date:  2004-11       Impact factor: 4.600

10.  Neuropsychological functioning in early onset psychotic disorders.

Authors:  Jon McClellan; Amy Prezbindowski; David Breiger; Chris McCurry
Journal:  Schizophr Res       Date:  2004-05-01       Impact factor: 4.939

View more
  10 in total

1.  Cognitive efficacy of quetiapine in early-onset first-episode psychosis: a 12-week open label trial.

Authors:  Sébastien Urben; Pierre Baumann; Sandra Barcellona; Muriel Hafil; Ulrich Preuss; Claire Peter-Favre; Stéphanie Clarke; Olivier Halfon; Laurent Holzer
Journal:  Psychiatr Q       Date:  2012-09

2.  First-Episode Psychosis Research: Time to Move Forward (by Looking Backwards).

Authors:  Celso Arango
Journal:  Schizophr Bull       Date:  2015-09-20       Impact factor: 9.306

Review 3.  Use of quetiapine in children and adolescents.

Authors:  Gabriele Masi; Annarita Milone; Stefania Veltri; Raffaella Iuliano; Chiara Pfanner; Simone Pisano
Journal:  Paediatr Drugs       Date:  2015-04       Impact factor: 3.022

4.  Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia.

Authors:  Qian Li; Yun Ai Su; Yi Liu; Jing Xu Chen; Yun Long Tan; Fu De Yang; Tian Mei Si
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

5.  Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review).

Authors:  Márcio G Soeiro-DE-Souza; Vasco Videira Dias; Giovanni Missio; Vicent Balanzá-Martinez; Leandro Valiengo; André F Carvalho; Ricardo Alberto Moreno
Journal:  Exp Ther Med       Date:  2015-01-23       Impact factor: 2.447

6.  Sex-specific cognitive abnormalities in early-onset psychosis.

Authors:  Miguel Ruiz-Veguilla; Josefa Moreno-Granados; Maria D Salcedo-Marin; Maria L Barrigon; Maria J Blanco-Morales; Evelio Igunza; Anselmo Cañabate; Maria D Garcia; Teresa Guijarro; Francisco Diaz-Atienza; Maite Ferrin
Journal:  Braz J Psychiatry       Date:  2016-01-09       Impact factor: 2.697

7.  The effects of anticholinergic medications on cognition in children: a systematic review and meta-analysis.

Authors:  Erica Ghezzi; Michelle Chan; Lisa M Kalisch Ellett; Tyler J Ross; Kathryn Richardson; Jun Ni Ho; Dayna Copley; Claire Steele; Hannah A D Keage
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

8.  Cognitive effects of atypical antipsychotic drugs in first-episode drug-naïve schizophrenic patients.

Authors:  Juan Wang; Maorong Hu; Xiaofeng Guo; Renrong Wu; Lehua Li; Jingping Zhao
Journal:  Neural Regen Res       Date:  2013-01-25       Impact factor: 5.135

9.  Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.

Authors:  Anne Katrine Pagsberg; Pia Jeppesen; Dea Gowers Klauber; Karsten Gjessing Jensen; Ditte Rudå; Marie Stentebjerg-Olesen; Peter Jantzen; Simone Rasmussen; Eva Ann-Sofie Saldeen; Maj-Britt Glenn Lauritsen; Niels Bilenberg; Anne Dorte Stenstrøm; Jesper Pedersen; Louise Nyvang; Sarah Madsen; Marlene B Lauritsen; Ditte Lammers Vernal; Per Hove Thomsen; Jakob Paludan; Thomas M Werge; Kristian Winge; Klaus Juul; Christian Gluud; Maria Skoog; Jørn Wetterslev; Jens Richardt M Jepsen; Christoph U Correll; Anders Fink-Jensen; Birgitte Fagerlund
Journal:  BMC Psychiatry       Date:  2014-07-11       Impact factor: 3.630

Review 10.  Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.

Authors:  Marco Solmi; Andrea Murru; Isabella Pacchiarotti; Juan Undurraga; Nicola Veronese; Michele Fornaro; Brendon Stubbs; Francesco Monaco; Eduard Vieta; Mary V Seeman; Christoph U Correll; André F Carvalho
Journal:  Ther Clin Risk Manag       Date:  2017-06-29       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.